AmpliSNiP Dementia Risk Assessment Panel (qPCR)
SNP28
The aging society presents us with challenges related to the diagnosis and therapy of dementia-related diseases. In Poland, approximately 500,000 people suffer from dementia, including 300,000 individuals with Alzheimer’s disease. Moreover, it is estimated that the number of patients will double in the next 20-25 years. Currently, only 15-20% of patients are correctly diagnosed and treated. Both the effectiveness and complications of therapies depend significantly on the genetic background.
The problem of dementia disproportionately affects women compared to men. Women account for two-thirds of Alzheimer’s disease patients. Approximately 1 in 6 women over the age of 65 develop Alzheimer’s compared to 1 in 11 men.
Diagnostic testAmpliSNiP Dementia Risk Assessment Panel (qPCR) kit enables the analysis of 16 key polymorphisms that influence the risk of Alzheimer’s disease.
AmpliSNiP Dementia Risk Assessment Panel (qPCR) kit contains 32 qPCR reaction setups allowing for the analysis of individual polymorphisms within the human genes under examination (two setups for each polymorphism analyzed). The kit includes a multi-well plate, where the analysis of individual allelic variants of the studied polymorphisms is conducted in separate wells of the plate. The qPCR reaction is duplex. Detection of individual variants is performed on the FAM channel, whereas second channel (HEX) is used for the detection of human DNA.
Table below lists all the polymorphisms and their allelic variants that are subjected to analysis.
| Gene | Polymorphism | Allelic variant |
| APP | rs463946 | G>C |
| APP | rs63750847 | G>A |
| NAT1 | rs1057126 | T>A |
| NAT1 | rs15561 | C>A |
| PICALM | rs541458 | C>T |
| PICALM | rs3851179 | A>G |
| PSEN1 | rs17125721 | A>G |
| TOMM40 | rs2075650 | A>G |